{"schema_version":"secwatch.filing_event.v1","accession":"0001764013-23-000020","form_type":"8-K","ticker":"IMVT","cik":"0001764013","company_name":"Immunovant, Inc.","filed_at":"2023-02-03T23:59:59+00:00","discovered_at":"2026-05-14T18:03:46.458171+00:00","generated_at":"2026-06-20T01:13:36.111318+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Immunovant reports widened Q3 net loss of $63.2M; cash $432.6M; batoclimab trials on track","bullets":["Net loss $63.2M ($0.49/share) vs $41.4M ($0.36) prior year; R&D spend rose to $42.3M.","Cash $432.6M expected to fund operations into second half of calendar 2025.","Phase 1 trial of IMVT-1402 to start early 2023; initial data expected mid-2023.","Phase 3 batoclimab in TED initiated; Phase 2b in CIDP started; topline results H1 2025 and H1 2024.","Batoclimab development for warm AIHA discontinued; indication reserved for IMVT-1402."],"urls":{"canonical":"https://secwatch.observer/filing/0001764013-23-000020","json":"https://secwatch.observer/filing/0001764013-23-000020.json","markdown":"https://secwatch.observer/filing/0001764013-23-000020.md","text":"https://secwatch.observer/filing/0001764013-23-000020.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1764013/000176401323000020/0001764013-23-000020-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1764013/000176401323000020/imvt-20230203.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-20T01:13:36.111318+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"a22fb62cbc66fd6fd0af4d34aacb22ab01389e0f","claim":"Immunovant, Inc. reported fiscal nine months ended December 31, 2022 results: net income $151.5 million ($1.26 per common share), EPS ($1.26 per common share).","evidence_excerpt":"Net loss was $151.5 million ($1.26 per common share) for the nine months ended December 31, 2022","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1764013/000176401323000020/0001764013-23-000020-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"fiscal nine months ended December 31, 2022"},{"label":"Net income","value":"$151.5 million ($1.26 per common share)"},{"label":"EPS","value":"($1.26 per common share)"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"},{"claim_id":"d0c811c5fe1d3e034d1b3489979ee2d39f10fd92","claim":"Immunovant, Inc. reported fiscal third quarter ended December 31, 2022 results: net income $63.2 million ($0.49 per common share), EPS ($0.49 per common share).","evidence_excerpt":"Net loss was $63.2 million ($0.49 per common share) for the three months ended December 31, 2022","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1764013/000176401323000020/0001764013-23-000020-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"fiscal third quarter ended December 31, 2022"},{"label":"Net income","value":"$63.2 million ($0.49 per common share)"},{"label":"EPS","value":"($0.49 per common share)"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}